

Amendment to the Claims

Please amend the claims as follows, without prejudice or disclaimer. This claim listing replaces all prior claim listings.

1-35. Cancelled.

36. (Withdrawn-currently amended) An isolated peptide ~~derived from BFA5~~ as shown in Table ~~IV~~ or V, where the peptide is not SEQ ID NO.: 28.

37. (Withdrawn, currently amended) A method for immunizing a host against the tumor antigen BFA5 comprising administering to the ~~patient~~ host an isolated peptide of claim 36.

38-66. Cancelled.

67. (Withdrawn-currently amended) An isolated peptide ~~of claim 36, the peptide being~~ selected from the group consisting of ~~LMDMQTFKA~~ (SEQ ID NO.:7), SEQ ID NO.:8, SEQ ID NO.:9, SEQ ID NO.:11, SEQ ID NO.:12, SEQ ID NO.:21, SEQ ID NO.:24, SEQ ID NO.:29, SEQ ID NO.:30, SEQ ID NO.:32, SEQ ID NO.:34, SEQ ID NO.:37, SQYSGQLKV (SEQ ID NO.:38), SEQ ID NO.:40, SEQ ID NO.:49, SEQ ID NO.:51, SEQ ID NO.:54, SEQ ID NO.:57, SEQ ID NO.:59, SEQ ID NO.:61, SEQ ID NO.:63, SEQ ID NO.:67, and ELCSVRLTL (SEQ ID NO.:70), SEQ ID NO.:72, SEQ ID NO.:74, SEQ ID NO.:77, SEQ ID NO.:78, SEQ ID NO.:81, SEQ ID NO.:84, and SEQ ID NO.:85, the peptide being immunogenic as determined by ELISPOT analysis of human T-cell cultures or human T cell cytotoxicity assay.

68. Cancelled.

69. (Withdrawn) A composition comprising an isolated peptide of claim 67 and a pharmaceutically acceptable carrier.

70. Cancelled.

71. (Withdrawn-currently amended) The method of claim 37 wherein the isolated peptide is administered alone or in combination with another agent wherein the individual components of the combination are administered simultaneously or separately from one another.

72. Cancelled.

73. (New) An isolated peptide having the amino acid sequence LMDMQTFKA (SEQ ID NO.:7).

74. (New) A composition comprising the isolated peptide of claim 73 in a pharmaceutically acceptable carrier.
75. (New) A composition for inducing an immune response in a host comprising the isolated peptide of claim 73 and at least one isolated peptide selected from the group consisting of SEQ ID NO.:8, SEQ ID NO.:9, SEQ ID NO.:11, SEQ ID NO.:12, SEQ ID NO.:21, SEQ ID NO.:24, SEQ ID NO.:28, SEQ ID NO.:29, SEQ ID NO.:30, SEQ ID NO.:32, SEQ ID NO.:34, SEQ ID NO.:37, SEQ ID NO.:38, SEQ ID NO.:40, SEQ ID NO.:49, SEQ ID NO.:51, SEQ ID NO.:54, SEQ ID NO.:57, SEQ ID NO.:59, SEQ ID NO.:61, SEQ ID NO.:63, SEQ ID NO.:67, SEQ ID NO.:70, SEQ ID NO.:72, SEQ ID NO.:74, SEQ ID NO.:77, SEQ ID NO.:78, SEQ ID NO.:81, SEQ ID NO.:84, SEQ ID NO.:85, SEQ ID NO.:99, SEQ ID NO.:100, SEQ ID NO.:101, SEQ ID NO.:102, SEQ ID NO.:103, and SEQ ID NO.:104, and a pharmaceutically acceptable carrier.
76. (New) A method for inducing an immune response in a host comprising administering to the host the isolated peptide of claim 73.
77. (New) A method for inducing an immune response in a host comprising administering to the host the composition of claim 74.
78. (New) A method for inducing an immune response in a host comprising administering to the host the composition of claim 75.